Authors

• Alessandra Bearz (ORCID: https://orcid.org/0000-0003-1020-2338)
• Tobias Raphael Overbeck (ORCID: https://orcid.org/0000-0002-2579-0171)
• Can Cai (ORCID: https://orcid.org/0000-0002-8253-8001)
• Tracey McCulloch
• Garrido Pilar
• Frances A. Shepherd (ORCID: https://orcid.org/0000-0002-3610-3533)
• Simantini Eddy
• Fabrice Barlési (ORCID: https://orcid.org/0000-0001-5793-3539)
• Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
• Armando Santoro (ORCID: https://orcid.org/0000-0003-1709-9492)
• Tae Min Kim
• Jon Zugazagoitia
• Eric Schaefer
• Daniel Shao-Weng Tan (ORCID: https://orcid.org/0009-0005-4021-2176)

Institutions

• Novartis (Switzerland) (CH)
• Centre National de la Recherche Scientifique (FR)
• University Health Network (CA)
• Humanitas University (IT)
• Inserm (FR)
• Aix-Marseille Université (FR)
• Université Paris-Saclay (FR)
• Institut Gustave Roussy (FR)
• Princess Margaret Cancer Centre (CA)
• Seoul National University Hospital (KR)
• Research Institute Hospital 12 de Octubre (ES)
• Highlands Oncology Group (US)
• Universitätsmedizin Göttingen (DE)
• Novartis (United States) (US)
• Vall d'Hebron Hospital Universitari (ES)
• Centro di Riferimento Oncologico (IT)
• National Cancer Centre Singapore (SG)
• Centre de Recherche en Cancérologie de Marseille (FR)
• Hospital Universitario Ramón y Cajal (ES)
• Bicêtre Hospital (FR)
• IRCCS Humanitas Research Hospital (IT)
• Vall d'Hebron Institute of Oncology (ES)
• Wake Forest University (US)

Publication Details

Journal

BMC Cancer

Published

2024-10-24

DOI

https://doi.org/10.1186/s12885-024-12841-2

Citations

6

Primary Topic

Cancer Immunotherapy and Biomarkers

Type

article

Field-Weighted Citation Impact

1.70

Funders

• Novartis Pharmaceuticals Corporation